How have AXGN and IMNM total returns compared?

Over the past 5 years, AXGN delivered 19.40% and IMNM delivered 2.88% annualized total return. Past performance doesn't predict future results.

AxoGen, Inc. (AXGN) vs Immunome, Inc. (IMNM)

A side-by-side comparison of AxoGen, Inc. and Immunome, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AXGN

AxoGen, Inc.

$2.00B

$37.22HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

IMNM

Immunome, Inc.

$2.02B

$21.17HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — AXGN vs IMNM

growth of $100 · dividends reinvested · last 6y

AXGN +220.0% (+21.4%/yr)IMNM +57.4% (+7.9%/yr)AXGN compounded faster over this window

AXGN IMNM

AXGN vs IMNM: by the numbers

•IMNM is the larger company ($2.02B vs $2.00B market cap).
•Both run net losses; AXGN's is the smaller (-13.36% vs -3059.99% net margin).

Metrics side by side

Valuation

Metric	AXGN	IMNM
Forward P/E	84.11	N/A
P/S ratio	7.97	N/A
P/B ratio	7.81	3.85
FCF yield	0.13%	N/A

Profitability

Metric	AXGN	IMNM
Gross margin	74.56%	57.43%
Operating margin	-5.12%	-3084.76%
Net margin	-13.36%	-3059.99%
ROE	-13.09%	-48.43%
ROIC	-4.68%	-51.06%

Growth (annualized)

Metric	AXGN	IMNM
Revenue CAGR (5Y)	13.99%	N/A
Total return CAGR (5Y)	19.40%	2.88%

Frequently asked

How have AXGN and IMNM total returns compared?: Over the past 5 years, AXGN delivered 19.40% and IMNM delivered 2.88% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AXGN analysis Full IMNM analysis Interactive comparison tool

Dig into the metrics

AxoGen ROE Immunome ROE AxoGen operating margin Immunome operating margin AxoGen revenue growth Immunome revenue growth AxoGen free cash flow Immunome free cash flow

AxoGen & Immunome appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.